SALT LAKE CITY, UT / ACCESSWIRE / May 8, 2023 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($.295) per share of common stock payable on July 6, 2023 to stockholders of record at the close of business on June 16, 2023. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.
Contact:
Brian Koopman
(801) 566-1200
| Last Trade: | US$55.52 |
| Daily Change: | -0.50 -0.89 |
| Daily Volume: | 19,281 |
| Market Cap: | US$180.440M |
November 05, 2024 October 29, 2024 July 25, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
